ScreenerHero

ARTV Artiva Biotherapeutics, Inc.

NAS · US · Healthcare · Biotechnology · artivabio.com
7.000USD-3.71%Mkt Cap: 342.23M $P/E: —

Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. Its lead product candidate…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap342.23M USD
Enterprise Value15.89M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-83.86M USD
Revenue/Share—
Last Price7.000 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees115
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-2.79
PEG—
EV/EBITDA-0.17
EV/Revenue—
P/S—
P/B1.02
EPS (TTM)-3.29
EPS (Forward)-2.61
52W Range
2.71036% of range14.53
52W High14.53 USD
52W Low2.710 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-76.26%
ROA-64.05%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-76.75M USD
CapEx (TTM)2.59M USD
FCF Margin—
FCF Yield-12.98%
Net Debt-339.54M USD
Net Debt/EBITDA3.63
Balance Sheet
Debt/Equity0.10
Current Ratio24.16
Quick Ratio24.06
Book Value/Sh7.12 USD
Cash/Share7.15 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.2 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)35.80 USD
Upside (mean)+411.4%
Target Range23.00 USD – 41.00 USD
23.00+411.4% to mean41.00
# Analysts5
Ownership
Shares Out.48.89M
Float19.43M
Insiders15.31%
Institutions84.22%
Short Interest
Short Ratio7.0d
Short % Float8.33%
Short % Out.4.22%
Shares Short2.07M
Short (prev mo.)2.10M
Technical
SMA 5010.07 (-30.5%)
SMA 2007.884 (-11.2%)
Beta2.41
S&P 52W Chg16.45%
Avg Vol (30d)442.31K
Avg Vol (10d)464.00K
Technical Indicators
RSI (14)29.7
MACD-0.9385
MACD Signal-0.9043
MACD Hist.-0.0342
BB Upper11.15 USD
BB Middle8.216 USD
BB Lower5.283 USD
BB Width71.39%
ATR (14)0.5585 USD
Vol Ratio (20d)0.62x